Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells

Journal of Immunology

Volumn 184, Issue 12, 2010, Pages 7297-7304

  Davis III, John M ^a   Knutson, Keith L ^b   Strausbauch, Michael A ^a   Crowson, Cynthia S ^a   Therneau, Terry M ^a   Wettstein, Peter J ^a   Matteson, Eric L ^a   Gabriel, Sherine E ^a,c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CD28 ANTIBODY; CD3 ANTIBODY; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 60; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; DISEASE SEVERITY; EX VIVO STUDY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; BLOOD; IMMUNOASSAY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CYTOKINES; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED;

EID: 77953624350     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0904180     Document Type: Article

References (55)

1. Cohen, S. B., M. D. Cohen, J. J. Cush, R. M. Fleischmann, P. J. Mease, M. H. Schiff, L. S. Simon, and A. L. Weaver. 2008. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J. Rheumatol. Suppl. 81: 4-30, quiz 31-34.
2. Bykerk, V. 2009. Unmet needs in rheumatoid arthritis. J. Rheumatol. Suppl. 82: 42-46.
3. Smolen, J. S., D. Aletaha, J. Grisar, K. Redlich, G. Steiner, and O. Wagner. 2008. The need for prognosticators in rheumatoid arthritis: biological and clinical markers: where are we now? Arthritis Res. Ther. 10: 208.
4. Wolfe, F., and K. Michaud. 2007. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. J. Rheumatol. 34: 1674-1683. (Pubitemid 47267609)
5. Wiles, N. J., D. G. Scott, E. M. Barrett, P. Merry, E. Arie, K. Gaffney, A. J. Silman, and D. P. Symmons. 2001. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann. Rheum. Dis. 60: 956-961.
6. Wolfe, F., and M. A. Cathey. 1991. The assessment and prediction of functional disability in rheumatoid arthritis. J. Rheumatol. 18: 1298-1306.
7. Smolen, J. S., C. Han, D. M. van der Heijde, P. Emery, J. M. Bathon, E. Keystone, R. N. Maini, J. R. Kalden, D. Aletaha, D. Baker, et al. 2009. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann. Rheum. Dis. 68: 823-827.
8. Turesson, C., W. M. O'Fallon, C. S. Crowson, S. E. Gabriel, and E. L. Matteson. 2003. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann. Rheum. Dis. 62: 722-727.
9. Gabriel, S. E., C. S. Crowson, H. M. Kremers, M. F. Doran, C. Turesson, W. M. O'Fallon, and E. L. Matteson. 2003. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 48: 54-58.
10. Wolfe, F., J. J. Rasker, M. Boers, G. A. Wells, and K. Michaud. 2007. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. Arthritis Rheum. 57: 935-942. (Pubitemid 47237319)
11. Brown, A. K., P. G. Conaghan, Z. Karim, M. A. Quinn, K. Ikeda, C. G. Peterfy, E. Hensor, R. J. Wakefield, P. J. O'Connor, and P. Emery. 2008. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 58: 2958-2967.
12. Sattar, N., D. W. McCarey, H. Capell, and I. B. McInnes. 2003. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108: 2957-2963.
13. Ku, I. A., J. B. Imboden, P. Y. Hsue, and P. Ganz. 2009. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ. J. 73: 977-985.
14. de Jager, W., H. te Velthuis, B. J. Prakken, W. Kuis, and G. T. Rijkers. 2003. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10: 133-139.
15. Arnett, F. C., S. M. Edworthy, D. A. Bloch, D. J. McShane, J. F. Fries, N. S. Cooper, L. A. Healey, S. R. Kaplan, M. H. Liang, H. S. Luthra, et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31: 315-324.
16. Cameron, S. B., M. C. Nawijn, W. W. Kum, H. F. Savelkoul, and A. W. Chow. 2001. Regulation of helper T cell responses to staphylococcal superantigens. Eur. Cytokine Netw. 12: 210-222.
17. + T cell IFNγ expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol. 17: 445-454.
18. Wang, Y. L., Y. Y. Zhang, Y. L. Zhou, Z. J. Zhu, Z. Q. Tang, Y. Jiang, L. Peng, G. Li, and X. H. Zhang. 2004. T-helper and T-cytotoxic cell subsets monitoring during active cytomegalovirus infection in liver transplantation. Transplant. Proc. 36: 1498-1499.
19. Compton, T., E. A. Kurt-Jones, K. W. Boehme, J. Belko, E. Latz, D. T. Golenbock, and R. W. Finberg. 2003. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J. Virol. 77: 4588-4596.
20. Tabeta, K., P. Georgel, E. Janssen, X. Du, K. Hoebe, K. Crozat, S. Mudd, L. Shamel, S. Sovath, J. Goode, et al. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 101: 3516-3521.
21. Rutz, M., J. Metzger, T. Gellert, P. Luppa, G. B. Lipford, H. Wagner, and S. Bauer. 2004. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 34: 2541-2550.
22. Calderwood, S. K., S. S. Mambula, P. J. Gray, Jr., and J. R. Theriault. 2007. Extracellular heat shock proteins in cell signaling. FEBS Lett. 581: 3689-3694.
23. Cohen-Sfady, M., G. Nussbaum, M. Pevsner-Fischer, F. Mor, P. Carmi, A. Zanin-Zhorov, O. Lider, and I. R. Cohen. 2005. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J. Immunol. 175: 3594-3602.
24. Vabulas, R. M., P. Ahmad-Nejad, C. da Costa, T. Miethke, C. J. Kirschning, H. Häcker, and H. Wagner. 2001. Endocytosed HSP60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem. 276: 31332-31339.
25. + regulatory T cell function via innate TLR2 signaling. J. Clin. Invest. 116: 2022-2032.
26. Rajaiah, R., and K. D. Moudgil. 2009. Heat-shock proteins can promote as well as regulate autoimmunity. Autoimmun. Rev. 8: 388-393.
27. Kruisbeek, A. M., E. Shevach, and A. M. Thornton. 2004. Proliferative assays for T cell function. Curr. Protoc. Immunol. Chapter 3: Unit 3.12.
28. Godoy-Ramirez, K., K. Franck, S. Mahdavifar, L. Andersson, and H. Gaines. 2004. Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometry. J. Immunol. Methods 292: 1-15.
29. + T cells are differentiated effector memory cells with antiviral functions. Blood 104: 478-486.
30. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
31. Harrell, F. E., Jr. 2001. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer, New York.
32. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361.
33. Brennan, F. M., and I. B. McInnes. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest. 118: 3537-3545.
34. Klareskog, L., P. Stolt, K. Lundberg, H. Källberg, C. Bengtsson, J. Grunewald, J. Rönnelid, H. E. Harris, A. K. Ulfgren, S. Rantapää-Dahlqvist, et al. 2006. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54: 38-46. (Pubitemid 43122184)
35. Djuardi, Y., H. Wibowo, T. Supali, I. Ariawan, R. G. Bredius, M. Yazdanbakhsh, L. C. Rodrigues, and E. Sartono. 2009. Determinants of the relationship between cytokine production in pregnant women and their infants. PLoS One 4: e7711.
36. Kawashima, M., and P. Miossec. 2004. Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis. Arthritis Res. Ther. 6: R39-R45.
37. Berg, L., J. Lampa, S. Rogberg, R. van Vollenhoven, and L. Klareskog. 2001. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFa receptors. Ann. Rheum. Dis. 60: 133-139.
38. Alex, P., P. Szodoray, N. Knowlton, I. M. Dozmorov, M. Turner, M. B. Frank, R. E. Arthur, L. Willis, D. Flinn, R. F. Hynd, et al. 2007. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin. Exp. Rheumatol. 25: 584-592.
39. Alex, P., N. C. Zachos, T. Nguyen, L. Gonzales, T. E. Chen, L. S. Conklin, M. Centola, and X. Li. 2009. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 15: 341-352.
40. Linkov, F., R. L. Ferris, Z. Yurkovetsky, A. Marrangoni, L. Velikokhatnaya, W. Gooding, B. Nolan, M. Winans, E. R. Siegel, A. Lokshin, and B. C. Stack. 2008. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases. Proteomics Clin. Appl. 2: 1575-1585.
41. Nolen, B. M., J. R. Marks, S. Ta'san, A. Rand, T. M. Luong, Y. Wang, K. Blackwell, and A. E. Lokshin. 2008. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 10: R45.
42. Dolhain, R. J., A. N. van der Heiden, N. T. ter Haar, F. C. Breedveld, and A. M. Miltenburg. 1996. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 39: 1961-1969.
43. Allen, M. E., S. P. Young, R. H. Michell, and P. A. Bacon. 1995. Altered T lymphocyte signaling in rheumatoid arthritis. Eur. J. Immunol. 25: 1547-1554.
44. Kusaba, M., J. Honda, T. Fukuda, and K. Oizumi. 1998. Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis. J. Rheumatol. 25: 1466-1471. (Pubitemid 28364747)
45. + T cells in rheumatoid arthritis by flow cytometry. J. Rheumatol. 27: 1128-1135.
46. MacHt, L. M., C. J. Elson, J. R. Kirwan, J. S. Gaston, A. G. Lamont, J. M. Thompson, and S. J. Thompson. 2000. Relationship between disease severity and responses by blood mononuclear cells from patients with rheumatoid arthritis to human heat-shock protein 60. Immunology 99: 208-214.
47. Kowalski, M. L., A. Wolska, J. Grzegorczyk, J. Hilt, M. Jarzebska, M. Drobniewski, M. Synder, and M. Kurowski. 2008. Increased responsiveness to Toll-like receptor 4 stimulation in peripheral blood mononuclear cells from patients with recent onset rheumatoid arthritis. Mediators Inflamm. 2008: 132732.
48. Leirisalo-Repo, M., L. Paimela, M. Jäättelä, S. Koskimies, and H. Repo. 1995. Production of TNF by monocytes of patients with early rheumatoid arthritis is increased. Scand. J. Rheumatol. 24: 366-371.
49. Fabris, M., B. Tolusso, E. Di Poi, P. Tomietto, S. Sacco, E. Gremese, and G. Ferraccioli. 2005. Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression. J. Rheumatol. 32: 998-1005. (Pubitemid 40828069)
50. Kohno, M., A. Tsutsumi, H. Matsui, M. Sugihara, T. Suzuki, M. Mamura, D. Goto, I. Matsumoto, S. Ito, T. Suguro, and T. Sumida. 2008. Interleukin-17 gene expression in patients with rheumatoid arthritis. Mod. Rheumatol. 18: 15-22.
51. Kawashima, M., and P. Miossec. 2005. Effect of treatment of rheumatoid arthritis with infliximab on IFN γ, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. Ann. Rheum. Dis. 64: 415-418.
52. Seitz, M., M. Zwicker, and B. Wider. 2001. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J. Rheumatol. 28: 496-501. (Pubitemid 32202649)
53. de Jager, W., B. J. Prakken, J. W. Bijlsma, W. Kuis, and G. T. Rijkers. 2005. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 300: 124-135.
54. Hitchon, C. A., P. Alex, L. B. Erdile, M. B. Frank, I. Dozmorov, Y. Tang, K. Wong, M. Centola, and H. S. El-Gabalawy. 2004. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J. Rheumatol. 31: 2336-2346.
55. Hueber, W., B. H. Tomooka, X. Zhao, B. A. Kidd, J. W. Drijfhout, J. F. Fries, W. J. van Venrooij, A. L. Metzger, M. C. Genovese, and W. H. Robinson. 2007. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis. 66: 712-719.